Understanding the differences in small cell lung cancer and how they affect treatment outcomes
Official title: Molecular and immunological heterogeneity of Small Cell Lung Cancer (SCLC) and its impact on relapse and therapeutic response
Funded at University of Tx Md Anderson Can Ctr · NIH-11092311 · Data updated 2026-11-12
This study is looking at the different ways small cell lung cancer can behave in order to find out how these differences affect treatment and chances of coming back, so that doctors can create better, personalized treatment plans just for you.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project start | June 1, 2021 |
| Project end | May 31, 2026 |
| Funding year | 2025 |
| Award (this year) | $605,520 |
| NIH project number | 5U01CA256780-05 |
| Project ID | NIH-11092311 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with small cell lung cancer who are seeking advanced treatment options.
✕Less likely to help
Patients with non-small cell lung cancer or those who are not diagnosed with any form of lung cancer may not benefit from this research.
What this research studies
This research investigates the molecular and immunological differences in small cell lung cancer (SCLC) to better understand how these variations impact treatment responses and the likelihood of relapse. By identifying distinct subtypes of SCLC based on specific genetic markers and immune characteristics, the study aims to develop more effective, personalized treatment strategies. Patients will be evaluated for their tumor's unique features, which may help in selecting the most appropriate therapies and improving overall outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more tailored and effective treatment options for patients with small cell lung cancer.
How similar studies have gone: Previous research has shown promise in understanding the molecular diversity of cancers, indicating that this approach could lead to significant advancements in treatment.
Where this research is happening
-
University of Tx Md Anderson Can Ctr
Houston, United States Active
Researchers
- Principal investigator: Byers, Lauren Averett — University of Tx Md Anderson Can Ctr
- Study coordinator: Byers, Lauren Averett
Related research
Other NIH-funded projects on the same topics.
-
Targeting DHX9 to boost viral-like immune response in Small Cell Lung Cancer
A scientist team is testing whether blocking a protein called DHX9 can make aggressive small cell lung cancer more visible to the immune system and more responsive to immunotherapy.
-
Blocking DHX9 to wake the immune system against small cell lung cancer
The team will block a protein called DHX9 in small cell lung cancer to trigger virus-like signals in tumors so they may respond better to immunotherapy.
-
Using a new approach to enhance immune response in Small Cell Lung Cancer
This study is exploring a new way to boost immunotherapy for people with Small Cell Lung Cancer by targeting a protein called DHX9, which could help turn less responsive tumors into ones that the immune system can better fight.
-
ABL kinase signaling and DNA collisions in small cell lung cancer
A drug target study in small cell lung cancer explores how blocking ABL kinase affects conflicts between transcription and DNA replication, which could influence tumor growth and survival.
-
XRN1 as a potential therapy target in lung cancer
A scientist-led program will study a cellular gene called XRN1 to see if turning it off can help treat non-small cell lung cancer.
-
Intermittent fasting with PD-1 inhibitors for non-small cell lung cancer
This grant tests whether a fasting-mimicking diet can boost the effectiveness of PD-1 inhibitors for people with non-small cell lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.